Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074982 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 676
- Enrollment target
NCT02074982 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 676 participants.
The verdict
NCT02074982, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 676 participants
- Enrollment target
Study Summary
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
Interventions
- DRUG AIN457 300 mg
- DRUG ustekinumab 45/90 mg
- DRUG placebo secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2014-02-26 |
| Est. Completion | 2016-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02074982
The ClinicalTrials.gov registry entry for NCT02074982 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 676 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AIN457 300 mg is the first listed.
NCT02074982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02074982 about?
NCT02074982 is a clinical study titled "Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis". This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
What is the current status of trial NCT02074982?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2014-02-26. Estimated completion is 2016-06-29.
What interventions are being tested in trial NCT02074982?
The interventions under investigation include: AIN457 300 mg (DRUG), ustekinumab 45/90 mg (DRUG), placebo secukinumab (DRUG).
Who is sponsoring clinical trial NCT02074982?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.